FDA Issues Draft Guidance for Industry, Considerations for Rescinding Breakthrough Therapy Designation

The U.S. FDA issued a draft guidance for industry titled Considerations for Rescinding Breakthrough Therapy Designation.
FDA Issues Draft Guidance for Industry, Considerations for Rescinding Breakthrough Therapy Designation

The U.S. FDA issued a draft guidance for industry titled Considerations for Rescinding Breakthrough Therapy Designation.